Repare Therapeutics
7210 Frederick-Banting
Suite 100
St-Laurent
Quebec
H4S 2A1
Canada
Website: http://www.reparerx.com/
Email: info@reparerx.com
About Repare Therapeutics
Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare’s platform combines a proprietary, high-throughput, CRISPR-enabled gene editing target discovery method with high-resolution protein crystallography, computational biology and clinical informatics. The company is backed by leading global healthcare investors including founding investor Versant Ventures and MPM Capital.YEAR FOUNDED:
2016
LEADERSHIP:
Founders: Daniel Durocher, PhD., Frank Sicheri, PhD and Agnel Sfeir, PhD
President & CEO: Lloyd M. Segal
EVP, Business & Corporate Development: Kim Seth
VP, Discovery: Cameron Black
EVP, Head of R&D: Michael Zinda
CAREER:
Please click here for Repare Therapeutics' job opportunities.
92 articles about Repare Therapeutics
-
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
5/5/2022
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022.
-
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification
4/20/2022
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification,
-
Hundreds of presentations on oncology research are highlighted at the AACR Annual Meeting, which is running from April 7 to 13 in New Orleans.
-
Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting
4/11/2022
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), today presented updated data from its ongoing Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific synthetic-lethal genomic alterations including those in the ATM gene (Ataxia-Telangiectasia mutated kinase) at the 2022 AACR Annual Meeting.
-
Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting
4/8/2022
Repare Therapeutics Inc., a leading clinical-stage precision oncology company, announced it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR, as well as two additional poster presentations at the upcoming 2022 AACR Annual Meeting held in New Orleans on April 8-13, 2022.
-
Repare Therapeutics to Present Comprehensive Phase 1 Monotherapy Data From the Phase 1/2 TRESR RP-3500 Clinical Trial and SNiPDx Panel at the 2022 AACR Annual Meeting
3/8/2022
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), today announced it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR trial of RP-3500 and a poster presentation of initial discovery and validation data of the novel Synthetic Lethal Interactions for Precision Diagnostics (SNiPDx) panel to understand allelic status of STEP2 genes at the upcoming 2022 AACR Annual Meeting,
-
Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1/2 TRESR Clinical Trial at the 2022 ESMO Targeted Anticancer Therapies Congress
3/7/2022
Repare Therapeutics Inc. today announced the presentation of monotherapy dose selection and safety data from its Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500 at the 2022 ESMO Targeted Anticancer Therapies (TAT) Congress.
-
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
3/1/2022
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences - Feb 03, 2022
2/3/2022
Repare Therapeutics Inc., a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, announced that members of its senior management team will participate in two virtual investor conferences in February.
-
Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022
1/7/2022
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today provided a corporate update and highlighted key milestones anticipated in 2022.
-
Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development
1/5/2022
Repare Therapeutics Inc. today announced the appointment of Philip Herman as its EVP Commercial & New Product Development.
-
Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/3/2022
Repare Therapeutics Inc. announced that Lloyd M. Segal, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:45 p.m. Eastern Time.
-
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors
12/21/2021
Repare Therapeutics Inc. today announced the first patient has been dosed in the Company’s Phase 1 clinical trial of RP-6306, a first-in-class small molecule candidate targeting PKMYT1, in combination with gemcitabine for the treatment of molecularly selected advanced solid tumors (NCT05147272) (the “MAGNETIC” trial).
-
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
11/15/2021
Repare Therapeutics Inc. today announced that members of its senior management team will participate in two virtual investor conferences in November.
-
Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
11/10/2021
Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
-
Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/2/2021
Repare Therapeutics Inc. announced the closing on November 1, 2021 of its upsized underwritten public offering of 4,600,000 common shares at a public offering price of $22.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 600,000 additional shares.
-
Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares - Oct 28, 2021
10/28/2021
Repare Therapeutics Inc., a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, announced the pricing of an upsized underwritten public offering of 4,000,000 of its common shares at a public offering price of $22.00 per share, for total gross proceeds of $88.0 million, before deducting underwriting commissions and offering expenses payable by Repare.
-
Repare Therapeutics Announces Proposed Public Offering of Common Shares
10/27/2021
Repare Therapeutics Inc. today announced the commencement of a proposed underwritten public offering of $75.0 million of its common shares.
-
Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference
10/18/2021
Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference
-
Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/8/2021
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the presentation of preliminary Phase 1 monotherapy clinical data from its Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500.